Please assess the completion status of the following clinical trial:

Trial Title: Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women and men 18 years or older with advanced solid tumor malignancy~* Ability to understand and voluntarily sign informed consent prior to undergoing any study-related assessments or procedures, as well as adhere to the study visit schedule and other protocol requirements.~* Local histologic or cytologic confirmation of HER2+ solid tumors by FISH amplification or IHC (3+)~* Patients must have received one prior approved therapy for metastatic disease and have not curable options~* For escalation: Documentation by established staging studies or clinical examination to have measurable or non-measurable metastatic disease per RECIST v1.1 criteria.~* For expansion: Documentation by established staging studies or clinical examination to have measurable metastatic disease per RECIST v1.1 criteria.~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.~* Adequate organ function:~* Absolute neutrophil count (ANC) ≥ 1.5 X 109/L~* Hemoglobin (Hgb) ≥9g/dL~* Platelets (plt) ≥ 100 x 109/L~* Potassium within normal range, or correctable with supplements;~* Serum calcium and magnesium within the normal range (or corrected with supplements)~* AST and ALT ≤2.5 x Upper Limit Normal (ULN)~* Serum total bilirubin ≤ 1.5 x ULN~* Serum creatinine ≤ 1.5 x ULN, or 24-hr clearance ≥ 60ml/min~* Serum albumin \> 3.0 g/dL~* Left ventricular ejection fraction of \>55% (or institutional lower normal value)~* Females of child-bearing potential (FCBP) must have negative serum pregnancy test within 7 days before starting study treatment and willingness to adhere to acceptable forms or birth control (a physician- approved contraceptive method: oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner)~FCBP is defined as a sexually mature women who:~* Have not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or,~* Have not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time during the preceding 12 consecutive months~* Must be willing to practice abstinence or use highly effective contraception for a minimum of 6 months following completion of study treatment (in addition to during study therapy)~* Male subjects with female partner of childbearing potential must agree to the use of a physician-approved contraceptive method throughout the course of the study and for 3 months after the last dose of the investigational product.~* Ability to take oral medications~Exclusion Criteria:~* Any significant medical condition, laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.~* Any condition that confounds the ability to interpret data from the study.~* Patients must have recovered from side effects from prior cancer-directed therapy to grade 1 or less (unless deemed not clinically significant by study investigator).~* Symptomatic central nervous system metastases. Subjects with brain metastases that have been previously treated and are stable for 4 weeks are allowed.~* Persistent diarrhea or malabsorption ≥ NCI CTCAE grade 1, despite medical management, ulcerative colitis, inflammatory bowel disease, resection of the stomach or small bowel, or other disease or condition significantly affecting gastrointestinal function.~* Unstable angina, significant cardiac arrhythmia, or New York Heart Association (NYHA) class III or IV congestive heart failure.~* Grade 2 or higher neuropathy~* Known history of: cardiac disease, heart failure or decreased left ventricular ejection fraction, significant clinical arrhythmias~* Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks, whichever is shorter, prior to starting study drug or who have not recovered from grade 2 or higher side effects of such therapy (except alopecia).~* Major surgery ≤ 2 weeks prior to starting a study drug or who have not recovered from side effects of such therapy.~* Known allergic reaction to neratinib, pertuzumab, trastuzumab, paclitaxel, or any of their components.~* Women who are pregnant or breast-feeding.~* Known active Human Immunodeficiency Virus (HIV) infection, Hepatitis B or C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 0 (Type: EXPERIMENTAL): 1. Neratinib: 80 mg, daily, oral~2. Paclitaxel: 80 mg/m2, weekly, intravenously~3. Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~4. Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously
- Cohort 1 (Type: EXPERIMENTAL): 1. Neratinib: 120 mg, daily, oral~2. Paclitaxel: 80 mg/m2, weekly, intravenously~3. Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~4. Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously
- Cohort 2 (Type: EXPERIMENTAL): 1. Neratinib: 160 mg, daily, oral~2. Paclitaxel: 80 mg/m2, weekly, intravenously~3. Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~4. Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously
- Cohort 3 (Type: EXPERIMENTAL): 1. Neratinib: 200 mg, daily, oral~2. Paclitaxel: 80 mg/m2, weekly, intravenously~3. Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~4. Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues